Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement
JACC: Cardiovascular Interventions · 2023
DOI: 10.1016/j.jcin.2023.02.039 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023. Verfasst von Kees H van Bergeijk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Stroke, Myocardial Infarction, Aortic Valve Stenosis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Stroke and bleeding are complications after transcatheter aortic valve replacement (TAVR). A higher incidence of bleeding and stroke has been reported in women, but the role of antithrombotic management pre- and post-TAVR has not been studied. OBJECTIVES: The study sought to compare bleeding and ischemic complications after TAVR between women and men stratified by antiplatelet and oral anticoagulant (OAC) regimen. METHODS: The POPular TAVI (Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation) trial was a randomized clinical trial to test the hypothesis that monotherapy with aspirin or OAC after TAVR is safer than the addition of clopidogrel. The primary endpoints of interest of this post hoc subanalysis were: 1) all bleeding; and 2) a composite of ischemic events consisting of stroke and myocardial infarction. Secondary endpoints were: 1) nonprocedural bleeding; 2) major or life-threatening bleeding; 3) minor bleeding; 4) stroke; 5) myocardial infarction; and 6) all-cause death. RESULTS: A total of 978 patients (466 [47.6%] women) were included in this study. All bleeding and the composite of myocardial infarction and stroke rates were similar between sexes (all bleeding: 106 [22.8%] women vs 121 [23.6%] men; P = 0.815; ischemic events: 26 [5.6%] vs 36 [7.0%]; P = 0.429). However, major or life-threatening bleeding occurred more often in women (58 [12.5%]) vs men (38 [7.4%]) (P = 0.011), most of which were access site bleedings. The use of aspirin pre- and post-TAVR increased major or life-threatening bleeding in women but not in men. CONCLUSIONS: After TAVR, overall bleeding and ischemic outcomes were similar between women and men. However, women had more major or life-threatening bleedings, especially those receiving aspirin pre- and post-TAVR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
- Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: j.j.wykrzykowska@umcg.nl.
- Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands.
Zitieren
APA
van Bergeijk, K. H., van Ginkel, D. J., Brouwer, J., Nijenhuis, V. J., van der Werf, H. W., van den Heuvel, A. F. M., Voors, A. A., Wykrzykowska, J. J., & Ten Berg, J. M. (2023). Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2023.02.039
Vancouver
van Bergeijk KH, van Ginkel DJ, Brouwer J, Nijenhuis VJ, van der Werf HW, van den Heuvel AFM, et al. Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2023. doi:10.1016/j.jcin.2023.02.039
BibTeX
@article{vanBergeijk2023,
author = {van Bergeijk, Kees H and van Ginkel, Dirk-Jan and Brouwer, Jorn and Nijenhuis, Vincent J and van der Werf, Hindrik W and van den Heuvel, Ad F M and Voors, Adriaan A and Wykrzykowska, Joanna J and Ten Berg, Jurriën M},
title = {Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
doi = {10.1016/j.jcin.2023.02.039}
}
EUVIMED